Insmed's Phase 3 ARISE Study Of Arikayce For Nontuberculous Mycobacterial Lung Infection Met Its Primary Objective Of Demonstrating That The Quality Of Life – Bronchiectasis Respiratory Domain Works Effectively As A Patient-reported Outcome Instrument
Portfolio Pulse from Benzinga Newsdesk
Insmed's Phase 3 ARISE study of Arikayce for Nontuberculous Mycobacterial Lung Infection has met its primary objective. The study demonstrated that the Quality of Life – Bronchiectasis Respiratory Domain works effectively as a patient-reported outcome instrument.
September 05, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Insmed's successful Phase 3 ARISE study of Arikayce could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. As the ARISE study is a significant development for Insmed, it is likely to have a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100